全球基础设施ETF-iShares(IGF)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IGF 全球基础设施ETF-iShares

盘后交易 07-22 17:35:07 EDT

50.02

+0.43

+0.87%

盘后50.02

+0.00+0.01%

16:05 EDT

最高50.11	最低49.73	成交量30.16万
今开49.85	昨收49.59	日振幅0.77%
总市值36.86亿	流通市值36.86亿	总股本7,370万
成交额1,508万	换手率0.41%	流通股本7,370万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"IGF","market":"US","secType":"STK","nameCN":"全球基础设施ETF-iShares","latestPrice":50.02,"timestamp":1721678400000,"preClose":49.59,"halted":0,"volume":301613,"hourTrading":{"tag":"盘后","latestPrice":50.0232,"preClose":50.02,"latestTime":"16:05 EDT","volume":45548,"amount":2278456.576956,"timestamp":1721678717281},"delay":0,"floatShares":73700000,"shares":73700000,"eps":0,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.43,"latestTime":"07-22 17:35:07 EDT","open":49.85,"high":50.11,"low":49.73,"amount":15081651.35516,"amplitude":0.007663,"askPrice":56.44,"askSize":100,"bidPrice":48.97,"bidSize":45,"shortable":3,"etf":1,"ttmEps":0,"exchange":"ARCA","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721692800000},"adr":0,"adjPreClose":49.59,"adrRate":0,"sharesOutstanding":73700000,"nav":49.6505,"aum":3659242292.2,"bidAskSpread":0.000606,"preHourTrading":{"tag":"盘前","latestPrice":49.59,"preClose":49.59,"latestTime":"08:02 EDT","volume":1,"amount":49.59,"timestamp":1721649740378},"postHourTrading":{"tag":"盘后","latestPrice":50.0232,"preClose":50.02,"latestTime":"16:05 EDT","volume":45548,"amount":2278456.576956,"timestamp":1721678717281},"volumeRatio":1.332669,"impliedVol":0.1141,"impliedVolPercentile":0.4542},"requestUrl":"/m/hq/s/IGF/tweets","defaultTab":"tweets","newsList":[{"id":"2437129437","title":"信达生物宣布替妥尤单抗（IGF-1R抗体）新药上市申请获国家药品监督管理局正式受理, 用于治疗甲状腺眼病","url":"https://stock-news.laohu8.com/highlight/detail?id=2437129437","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437129437?lang=zh_cn&edition=full","pubTime":"2024-05-21 08:41","pubTimestamp":1716252060,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年5月21日 /美通社/ --信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布：替妥尤单抗注射液的新药上市申请已获中国国家药品监督管理局药品审评中心受理，用于甲状腺眼病的治疗。期待替妥尤单抗能早日上市，造福中国TED患者。2024年5月，替妥尤单抗的首个NDA获NMPA受理，用于TED的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4419306_ZH19306_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2328871848.SGD","IGF","01801","BK1583","IVBIY","BK1161","BK4139","LU1969619763.USD","BK1589"],"gpt_icon":0},{"id":"2417203694","title":"信达生物在2024年亚太眼科学会年会和国际内分泌学大会上口头报告IBI311（抗IGF-1R单抗）的两项临床研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2417203694","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417203694?lang=zh_cn&edition=full","pubTime":"2024-03-07 10:43","pubTimestamp":1709779380,"startTime":"0","endTime":"0","summary":"研究期间，IBI311各剂量组抗药抗体均检测为阴性。提示健康受试者接受不同剂量下单次静脉注射IBI311的安全性和耐受性良好，且PK特征支持后续临床开发的剂量选择。在12周后，所有受试者将继续接受IBI311治疗，持续至第21周。安全性：总体安全性良好，绝大多数AE为轻度或中度，IBI311组无导致药物停用/暂停的治疗期不良事件。目前IBI311 的III期临床试验已经完成，主要终点顺利达成。尤其是对于合并显著突眼的TED，靶向IGF-1R的替妥尤单抗可作为首选。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4355203_ZH55203_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1969619763.USD","IGF","BK1589","LU2328871848.SGD","BK1583","BK4139","IVBIY","01801","BK1161"],"gpt_icon":0},{"id":"2414815217","title":"港股异动 | 信达生物(01801)再涨超4% IGF-1R抗体III期临床达主要终点 计划递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2414815217","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414815217?lang=zh_cn&edition=full","pubTime":"2024-02-27 11:52","pubTimestamp":1709005959,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物再涨超4%，月内累涨超30%。消息面上，2月20日，信达生物宣布其研发的重组抗胰岛素样生长因子1受体抗体注射液在中国甲状腺眼病受试者中开展的III期注册临床研究达成主要终点。高盛维持信达生物\"买入\"评级，目标价由57.4港元调高至60.66港元。高盛估计，信达生物新药IBI311治疗效果令人满意，预计可于2025年于内地推出上市，2033年销售峰值达10亿元人民币，这假设约有2.5万名甲状腺眼病病人受药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1077314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2328871848.SGD","IGF","07226","01801","YINN","YANG","BK1583","BK4134","BK4585","BK1161","III","LU1969619763.USD","BK1589"],"gpt_icon":0},{"id":"2412167711","title":"信达生物宣布IBI311（抗IGF-1R抗体）治疗甲状腺眼病的III期临床研究（RESTORE-1）达成主要终点，计划将递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2412167711","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2412167711?lang=zh_cn&edition=full","pubTime":"2024-02-20 08:00","pubTimestamp":1708387200,"startTime":"0","endTime":"0","summary":"信达生物计划向国家药品监督管理局药品审评中心递交IBI311治疗TED的新药上市申请。整个研究期间IBI311整体安全性良好，未发生严重不良事件。RESTORE-1研究III期阶段的疗效趋势和安全性特征与II期阶段结果高度一致。当前国内尚无用于治疗甲状腺眼病的靶向药物获批，治疗手段有限。信达生物管线布局一直以未满足医学需求为导向，公司自主研发的基于IGF-1R靶点的单克隆抗体IBI311在RESTORE-1研究中展示出治疗TED效果显著、安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4339801_ZH39801_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK4134","LU1969619763.USD","BK1583","IGF","LU2328871848.SGD","III","IVBIY","BK1589","01801","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0314},{"period":"3month","weight":0.0671},{"period":"6month","weight":0.0945},{"period":"1year","weight":0.0418},{"period":"ytd","weight":0.054}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":-0.004463},{"month":2,"riseRate":0.705882,"avgChangeRate":-0.00609},{"month":3,"riseRate":0.764706,"avgChangeRate":0.012882},{"month":4,"riseRate":0.823529,"avgChangeRate":0.024338},{"month":5,"riseRate":0.470588,"avgChangeRate":0.003408},{"month":6,"riseRate":0.294118,"avgChangeRate":-0.019498},{"month":7,"riseRate":0.764706,"avgChangeRate":0.017986},{"month":8,"riseRate":0.4375,"avgChangeRate":-0.013602},{"month":9,"riseRate":0.375,"avgChangeRate":-0.012957},{"month":10,"riseRate":0.625,"avgChangeRate":0.001537},{"month":11,"riseRate":0.375,"avgChangeRate":0.006371},{"month":12,"riseRate":0.5625,"avgChangeRate":0.003059}],"exchange":"ARCA","name":"全球基础设施ETF-iShares","nameEN":"iShares Global Infrastructure ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"全球基础设施ETF-iShares(IGF)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供全球基础设施ETF-iShares(IGF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"全球基础设施ETF-iShares,IGF,全球基础设施ETF-iShares股票,全球基础设施ETF-iShares股票老虎,全球基础设施ETF-iShares股票老虎国际,全球基础设施ETF-iShares行情,全球基础设施ETF-iShares股票行情,全球基础设施ETF-iShares股价,全球基础设施ETF-iShares股市,全球基础设施ETF-iShares股票价格,全球基础设施ETF-iShares股票交易,全球基础设施ETF-iShares股票购买,全球基础设施ETF-iShares股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"全球基础设施ETF-iShares(IGF)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供全球基础设施ETF-iShares(IGF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}